PMID- 38287111
OWN - NLM
STAT- Publisher
LR  - 20240129
IS  - 1476-5454 (Electronic)
IS  - 0950-222X (Linking)
DP  - 2024 Jan 29
TI  - Innate immune responsive inflammation in development of progressive myopia.
LID - 10.1038/s41433-024-02947-z [doi]
AB  - PURPOSE: Inflammation has been implicated for development of myopia. It is not 
      clear when inflammation is kicked in during the course of myopia, and what 
      characteristics of the inflammation. In this study, we tested for cytokines from 
      aqueous humour of eyes with wide spectrum of refractive status for profiling the 
      inflammation. METHODS: Aqueous humour of 142 patient eyes were tested for soluble 
      intercellular adhesion molecule 1 (sICAM-1), monocyte chemoattractant protein-1 
      (MCP-1), and transforming growth factor-beta 2 (TGF-beta2) using an enzyme-linked 
      immunosorbent assay (ELISA). Eye globe axial length of these patients ranged from 
      emmetropia to high myopia. RESULTS: Of 142 patients, an average axial length is 
      25.51 +/- 3.31 mm, with a range of 21.56-34.37 mm. There are 36 cases in lower 25 
      percentile, 37 cases in upper 25 percentile, and 69 case in the middle 50 
      percentile. sICAM-1 and MCP-1 were significantly higher in the eyes with 
      staphyloma (407.48 pg/mL, 312.31 pg/mL, n = 33) or macular schisis 
      (445.86 pg/mL,345.33 pg/mL, n = 19) than that in the eyes without these changes 
      (206.44 pg/mL, 244.76 pg/mL, n = 107). All three cytokines level was 
      significantly associated with eye globe axial in a positive mode while adjusting 
      for the age and sex. Strength of the association was the greatest for sICAM-1 and 
      the weakest for TGF- beta2. MCP-1 was in between. CONCLUSION: sICAM-1 and MCP-1 in 
      ocular fluid may be indicative biomarkers for progressive high myopia and the 
      underneath autoimmune inflammation. sICAM-1 may be used as a monitoring biomarker 
      for development of pathologic myopia.
CI  - (c) 2024. The Author(s), under exclusive licence to The Royal College of 
      Ophthalmologists.
FAU - Pan, Suqi
AU  - Pan S
AUID- ORCID: 0000-0001-5475-7357
AD  - The Affiliated Ningbo Eye Hospital of Wenzhou Medical University, Ningbo, China.
FAU - Yuan, Jianshu
AU  - Yuan J
AD  - The Affiliated Ningbo Eye Hospital of Wenzhou Medical University, Ningbo, China.
FAU - Jin, Yuanhui
AU  - Jin Y
AD  - Department of Ophthalmology, Dongyang People's Hospital, Dongyang, China.
FAU - Liu, Xiaotian
AU  - Liu X
AD  - The Affiliated Ningbo Eye Hospital of Wenzhou Medical University, Ningbo, China.
FAU - Wu, Shanjun
AU  - Wu S
AD  - The Affiliated Ningbo Eye Hospital of Wenzhou Medical University, Ningbo, China.
FAU - Wang, Yuwen
AU  - Wang Y
AD  - The Affiliated Ningbo Eye Hospital of Wenzhou Medical University, Ningbo, China.
FAU - Yao, Hongyan
AU  - Yao H
AD  - The Affiliated Ningbo Eye Hospital of Wenzhou Medical University, Ningbo, China.
FAU - Cheng, Lingyun
AU  - Cheng L
AUID- ORCID: 0000-0002-0748-5173
AD  - Jacob's Retina Center at Shiley Eye Institute, Department of Ophthalmology, 
      University of California San Diego, La Jolla, CA, USA. l1cheng@health.ucsd.edu.
LA  - eng
PT  - Journal Article
DEP - 20240129
PL  - England
TA  - Eye (Lond)
JT  - Eye (London, England)
JID - 8703986
SB  - IM
EDAT- 2024/01/30 00:42
MHDA- 2024/01/30 00:42
CRDT- 2024/01/29 23:31
PHST- 2023/03/16 00:00 [received]
PHST- 2024/01/17 00:00 [accepted]
PHST- 2024/01/06 00:00 [revised]
PHST- 2024/01/30 00:42 [medline]
PHST- 2024/01/30 00:42 [pubmed]
PHST- 2024/01/29 23:31 [entrez]
AID - 10.1038/s41433-024-02947-z [pii]
AID - 10.1038/s41433-024-02947-z [doi]
PST - aheadofprint
SO  - Eye (Lond). 2024 Jan 29. doi: 10.1038/s41433-024-02947-z.